Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CARsgen Therapeutics Holdings Ltd. ( (HK:2171) ) just unveiled an announcement.
CARsgen Therapeutics Holdings Ltd. announced the passing of Mr. Bingsen Guo, a non-executive director who had been with the company for over a decade. Mr. Guo played a crucial role in the company’s strategic transformation and development, providing key support during critical business initiatives. His contributions have been instrumental in overcoming challenges and ensuring the company’s steady growth. The board expressed its condolences to Mr. Guo’s family and acknowledged his significant impact on the company’s success.
The most recent analyst rating on (HK:2171) stock is a Sell with a HK$14.92 price target. To see the full list of analyst forecasts on CARsgen Therapeutics Holdings Ltd. stock, see the HK:2171 Stock Forecast page.
More about CARsgen Therapeutics Holdings Ltd.
CARsgen Therapeutics Holdings Ltd. is a biotechnology company focused on the development of innovative CAR-T cell therapies for the treatment of cancer. The company operates in the biopharmaceutical industry and is dedicated to advancing its pipeline of products to address unmet medical needs in the oncology market.
Average Trading Volume: 2,607,231
Technical Sentiment Signal: Hold
Current Market Cap: HK$11.68B
See more data about 2171 stock on TipRanks’ Stock Analysis page.